Evidence map›Paper›PMID 36393850›Full record

ArticleFrontiers in cell and developmental biology2022

New functions of C3G in platelet biology: Contribution to ischemia-induced angiogenesis, tumor metastasis and TPO clearance.

Luis Hernández-Cano, Cristina Fernández-Infante, Óscar Herranz, Pablo Berrocal, Francisco S Lozano, Manuel A Sánchez-Martín, Almudena Porras, Carmen Guerrero

Open access · goldAbstract read
In one paragraph

Article in Frontiers in cell and developmental biology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.3field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Luis Hernández-CanoInstituto de Biología Molecular y Celular del Cáncer (IMBCC), USAL-CSIC, Salamanca, Spain.
Cristina Fernández-InfanteInstituto de Biología Molecular y Celular del Cáncer (IMBCC), USAL-CSIC, Salamanca, Spain.
Óscar HerranzInstituto de Biología Molecular y Celular del Cáncer (IMBCC), USAL-CSIC, Salamanca, Spain.
Pablo BerrocalInstituto de Biología Molecular y Celular del Cáncer (IMBCC), USAL-CSIC, Salamanca, Spain.
Francisco S LozanoInstituto de Investigación Biomédica de Salamanca (IBSAL), Salamanca, Spain.
Manuel A Sánchez-MartínInstituto de Investigación Biomédica de Salamanca (IBSAL), Salamanca, Spain.
Almudena PorrasDepartamento de Bioquímica y Biología Molecular, Facultad de Farmacia, Universidad Complutense de Madrid, Madrid, Spain.
Carmen GuerreroInstituto de Biología Molecular y Celular del Cáncer (IMBCC), USAL-CSIC, Salamanca, Spain.
Centro de Investigación del Cáncer · ESInstituto de Investigación Biomédica de Salamanca · ESInstituto de Investigación Sanitaria del Hospital Clínico San Carlos · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

C3G is a Rap1 guanine nucleotide exchange factor that controls platelet activation, aggregation, and the release of α-granule content. Transgenic expression of C3G in platelets produces a net proangiogenic secretome through the retention of thrombospondin-1. In a physiological context, C3G also promotes megakaryocyte maturation and proplatelet formation, but without affecting mature platelet production. The aim of this work is to investigate whether C3G is involved in pathological megakaryopoiesis, as well as its specific role in platelet mediated angiogenesis and tumor metastasis. Using megakaryocyte-specific C3G knockout and transgenic mouse models, we found that both C3G overexpression and deletion promoted platelet-mediated angiogenesis, induced by tumor cell implantation or hindlimb ischemia, through differential release of proangiogenic and antiangiogenic factors. However, only C3G deletion resulted in a higher recruitment of hemangiocytes from the bone marrow. In addition, C3G null expression enhanced thrombopoietin (TPO)-induced platelet production, associated with reduced TPO plasma levels. Moreover, after 5-fluorouracil-induced platelet depletion and rebound, C3G knockout mice showed a defective return to homeostatic platelet levels, indicating impaired platelet turnover. Mechanistically, C3G promotes c-Mpl ubiquitination by inducing Src-mediated c-Cbl phosphorylation and participates in c-Mpl degradation

Indexed as

C3Gc-Mplischemia-induced angiogenesisplatelet-mediated metastasisplateletsRap1RapGEF1thrombopoietin

Identifiers

PMID36393850
PMCPMC9661425
OpenAlexW4307688886

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.